Insider Selling: Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $2,664,822.66 in Stock

Posted by Geri Gentry on Oct 29th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 84,894 shares of the stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66. Following the sale, the insider directly owned 165,953 shares in the company, valued at $5,209,264.67. This trade represents a 33.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total transaction of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total value of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total transaction of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.
On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Stock Performance

ALMR traded down $0.26 during trading on Thursday, reaching $34.04. 496,143 shares of the stock were exchanged, compared to its average volume of 416,412. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.23 and a current ratio of 11.85. The business’s 50 day moving average price is $30.76. Alamar Biosciences, Inc. has a twelve month low of $18.84 and a twelve month high of $39.61. The company has a market cap of $2.36 billion and a PE ratio of -17.37.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.14. The company had revenue of $29.43 million for the quarter. Equities research analysts predict that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ALMR shares. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Stifel Nicolaus lifted their target price on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their price target on Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alamar Biosciences currently has a consensus rating of “Hold” and a consensus price target of $31.80.

Read Our Latest Stock Report on Alamar Biosciences

Institutional Trading of Alamar Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in Alamar Biosciences in the 3rd quarter worth about $196,000. Squarepoint Ops LLC purchased a new position in Alamar Biosciences in the second quarter worth $283,000. Sumitomo Mitsui Trust Group Inc. raised its position in Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after purchasing an additional 10,461 shares in the last quarter. State Street Corp bought a new position in shares of Alamar Biosciences during the 2nd quarter valued at about $3,930,000. Finally, Wellington Management Group LLP purchased a new position in shares of Alamar Biosciences during the 2nd quarter valued at about $12,407,000.

Alamar Biosciences Company Profile

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.